Topic Menu
► Topic MenuTopic Editors



Targeting Signaling Networks for Cancer Therapy
Topic Information
Dear Colleagues,
We know that cancer-associated signaling networks, HER signaling, EGF signaling, Wnt signaling, Notch signaling, TGF-β pathway, mTOR pathway, PD-1/PD-L1 axis, etc., are all involved in normal cell survival regulation. However, any abnormal modulation might result in uncontrollable cell growth, or a tumor. To survive, tumor cells must try to avoid attacks from the native immune system. Cancer cells interact with nearby healthy host cells through the same signaling networks to prevent them from being removed. The dysregulated signaling factors of cancer cells provide possible targets, which could allow for us to control them. Cancer vaccines, chemical drugs, small molecules, monoclonal antibodies, etc., could modify the interactions between cancer and host cells, as well as adjusting the tumor microenvironment and active immune response against cancer cells. However, current cancer treatments, either traditional chemotherapy or the latest checkpoint inhibition and cell immunotherapy, have limitations and some serious side effects, such as damaging conditions in the body, drug resistance, partial response, tumor metastasis, etc. This Special Issue will focus on the current state of cancer signaling network research, from bench work to bedside clinical daily practice, to better understand carcinogenesis, lower toxicity and develop more effective treatment strategies against cancer.
Prof. Dr. Renato Bassan
Prof. Dr. Jose-Maria Ribera
Dr. Linlin Guo
Topic Editors
Keywords
- cancer research
- cancer therapy
- signaling pathway
- HER
- EGF
- Wnt
- Notch
- TGF-β
- mTOR
- PD-1/PD-L1
Participating Journals
Journal Name | Impact Factor | CiteScore | Launched Year | First Decision (median) | APC |
---|---|---|---|---|---|
![]()
Biology
|
3.6 | 5.7 | 2012 | 16.4 Days | CHF 2700 |
![]()
Biomedicines
|
3.9 | 5.2 | 2013 | 14.6 Days | CHF 2600 |
![]()
Cancers
|
4.5 | 8.0 | 2009 | 17.4 Days | CHF 2900 |
![]()
Current Oncology
|
2.8 | 3.3 | 1994 | 19.8 Days | CHF 2200 |
![]()
Onco
|
- | - | 2021 | 27.8 Days | CHF 1000 |
Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.
MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:
- Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
- Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
- Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
- Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
- Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.